

HCQ + Azithromycin



Observational study (3/2 to 3/21, 2020)



80 patients with PCR confirmed SARS-CoV2 from NP sample at a University hospital in France



HCQ 200mg PO TID x 10d + Azithromycin 500mg PO x1d, then 250mg PO qdaily x4d



Baseline Characteristics

	n	%
Time between onset of symptoms and hospitalisation		
Mean ± SD		4.8 ± 5,6
Min - Max	1	17
Clinical classification		
Asymptomatic	4	5.0
Upper respiratory tract infection symptoms	33	41.2
Lower respiratory tract infection symptoms	43	53.8
Fever	12	15.0

Baseline EKG:
If QTc > 500ms, medication not started, or discontinued



Baseline Characteristics

NEWS score (N = 75, 5 missing data)

0 – 4 (low)	69	92.0
5 – 6 (medium)	4	5.3
≥ 7 (high)	2	2.7

Pulmonary CT-scanner within 72 hours of admission

Not performed	16	20.0
Not consistent with pneumonia	21	26.2
Consistent with pneumonia	43	53.8

National Early Warning Score for CoVID-19 patients (NEWS):
Age, respiration rate, oxygen saturation, temperature, SBP, pulse, level of consciousness



Clinical Criteria



Criteria for contagiousness:

Patients with a PCR CT value of <34 were considered presumably contagious

Patients with positive culture were considered contagious



Criteria for discharge:

Patients with two negative NP samples by PCR (CT value ≥ 35) were discharged.

Starting on 3/18, patients with a single NP sample with a PCR CT value ≥ 34 were discharged to home or other units



Cycle Times (CT)

- CT is a value used to infer viral load
- The **HIGHER** viral load, the **LOWER** CT
 - Less cycles to amplify viral replications
- The **LOWER** viral load, the **HIGHER** CT
 - More cycles to amplify viral replications



Primary Endpoints



Clinical course requiring oxygen therapy or transfer to the ICU after at least three days of treatment



Contagiousness as assessed by PCR and culture



Length of hospital stay



Outcomes

Table 3: Treatment and outcome

	n	%
Oxygen therapy	12	15.0
Transfer to intensive care unit	3	3.8
Death	1	1.2
Discharged	65	81.2
Currently hospitalised		
ICU	1	1.2
Infectious disease ward	13	16.2



Outcomes

Possible adverse events


Nausea or vomiting	2	2.5
Diarrhoea	4	5.0
Blurred vision*	1	1.2

Time from treatment initiation to discharge (n = 65)


Mean \pm SD		4.1 \pm 2.2
Min - Max	1	10



Contagiousness Impairment PCR (CT < 34)



Contagiousness Impairment Viral Culture



Author's Conclusion

- Viral load tested by PCR, were negative in 93% patients at Day8
- Viral cultures were negative in 98% patients at Day5
- Median viral shedding from Chinese studies 20 days (8-37 days)
- Clearing viral carriage may decrease risk of transmission with a mean length of stay of five days
- Limitation:
 - No control group, causal association?
 - Adverse effects: QTc prolongation
 - Surrogate endpoints

